Abstract
AA-amyloidosis is a disease characterized by abnormal deposition of serum A amyloid (SAA) peptide along with other components in various organs. The disease is a complication of inflammatory conditions that cause persistent high levels of the acute phase reactant SAA in plasma. In experimental animal models, the deposited amyloid is resolved when the inflammation is stopped, suggesting that there is an efficient clearance mechanism for the amyloid. As heparan sulfate (HS) is one of the major components in the amyloid, its metabolism is expected to affect the pathology of AA amyloidosis. In this study, we investigated the effect of heparanase, a HS degradation enzyme, in resolution of the AA amyloid. The transgenic mice deficient in heparanase (Hpa-KO) produced a similar level of SAA in plasma as the wildtype control (Ctr) mice upon induction by injection of AEF (amyloid enhancing factor) and inflammatory stimuli. The induction resulted in formation of SAA amyloid 7-days post treatment in the spleen that displayed a comparable degree of amyloid load in both groups. The amyloid became significantly less in the Hpa-KO spleen than in the Ctr spleen 10-days post treatment, and was completely resolved in the Hpa-KO spleen on day 21 post induction, while a substantial amount was still detected in the Ctr spleen. The rapid clearance of the amyloid in the Hpa-KO mice can be ascribed to upregulated matrix metalloproteases (MMPs) that are believed to contribute to degradation of the protein components in the AA amyloid. The results indicate that both heparanase and MMPs play important parts in the pathological process of AA amyloidosis.
Introduction
Systemic AA amyloidosis is a severe clinical condition characterized by the extracellular accumulation of Serum Amyloid A (SAA) protein as insoluble fibrils. These deposits primarily affect the spleen, liver, and kidneys, leading to progressive organ dysfunction. The pathogenesis is closely linked to chronic inflammatory states, which drive high plasma concentrations of SAA, an acute-phase reactant.
A critical non-protein component of these amyloid deposits is heparan sulfate (HS), a complex glycosaminoglycan found in the extracellular matrix. HS is known to promote the misfolding and aggregation of SAA into fibrils and provides structural stability to the resulting deposits. Heparanase (Hpa) is the only known mammalian endoglucuronidase capable of degrading HS. Logically, it has long been hypothesized that heparanase activity would be necessary for the clearance of amyloid by breaking down the HS scaffold. Conversely, a lack of heparanase was expected to stabilize amyloid deposits due to the presence of longer, intact HS chains.
Experimental Approach
To test this hypothesis, researchers utilized a heparanase-knockout (Hpa-KO) mouse model. Amyloidosis was induced in both Hpa-KO and wild-type control (Ctr) mice using a standard protocol involving the injection of Amyloid Enhancing Factor (AEF) followed by silver nitrate to trigger acute inflammation.
The progression and resolution of the disease were monitored over a 72-day period. The researchers employed a multi-faceted analytical approach:
- Histological Quantification: Congo red staining and polarized light microscopy were used to measure amyloid load in the spleen, liver, and kidneys.
- Molecular Analysis: Quantitative PCR (Q-PCR) and Western blotting were used to track the expression of SAA and various proteases.
- Protease Activity: The study specifically looked at Matrix Metalloproteases (MMPs), which are known to degrade extracellular matrix proteins.
- In Vitro Validation: An incubation assay was performed to determine if MMP-9 could directly degrade AEF.
Results and Discussion
The Resolution Paradox
The initial phase of the experiment showed that both Hpa-KO and control mice developed similar amyloid loads by day 7 post-induction. This indicated that heparanase is not strictly required for the initial formation of amyloid fibrils.
However, the resolution phase yielded a surprising result. Instead of the expected delay in clearance, the Hpa-KO mice resolved their amyloid deposits significantly faster than the controls. By day 10, the amyloid load in Hpa-KO spleens was already lower, and by day 21, the deposits were completely cleared. In contrast, the control mice still exhibited substantial amyloid presence at the same time points.
Compensatory Upregulation of MMPs
The researchers investigated why the absence of a key degradation enzyme led to faster clearance. They discovered a compensatory mechanism involving Matrix Metalloproteases. In the Hpa-KO mice, there was a significant upregulation of MMP-2 in the spleen and MMP-9 in the liver.
This upregulation appears to be a biological "fail-safe." When the sugar-degrading enzyme (heparanase) is missing, the body overcompensates by increasing the production of protein-degrading enzymes (MMPs). These proteases aggressively target the SAA protein component of the amyloid fibrils. The in vitro finding that MMP-9 can directly degrade AEF supports the conclusion that these enzymes are the primary drivers of the accelerated resolution observed in the knockout mice.
Tissue-Specific Responses
Interestingly, the study noted that the specific MMP upregulated varied by organ. While MMP-2 was the dominant protease in the spleen, MMP-9 played a larger role in the liver. This suggests that the body's response to amyloid deposition is tailored to the specific microenvironment of each organ.
Conclusion
This study challenges the conventional understanding of heparanase's role in amyloidosis. While HS is a necessary partner for amyloid formation, its degradation by heparanase is not the only pathway for resolution. The discovery that MMPs can be upregulated to clear amyloid in the absence of heparanase opens new avenues for therapeutic research. If pharmacological agents can be developed to safely induce specific MMPs, they might provide a potent new strategy for treating patients suffering from systemic amyloidosis.
Summary updated